Literature DB >> 15665940

Selective accumulation of monoclonal antibodies against neurospecific enolase in brain tissue of rats with middle cerebral artery occlusion.

V P Chekhonin1, S V Lebedev, I A Ryabukhin, S V Petrov, O I Gurina, T B Dmitrieva, A I Volkov, I A Kashparov, Yu S Skoblov.   

Abstract

Preparations of I(125)-labeled monoclonal antibodies against neurospecific enolase and mouse plasma IgG1 were injected intravenously to rats immediately after unilateral occlusion of the middle cerebral artery. Radioactivity of I(125)-labeled monoclonal antibodies against neurospecific enolase in the brain tissue progressively increased, reached a maximum by the 48th hour, and remained practically unchanged after 72 h. At the same time radioactivity of labeled IgG1 in the brain tissue and radioactivity of both preparations in the blood, liver, spleen, kidneys, heart, and lungs decreased over 72 h. Selective accumulation of I(125)-labeled monoclonal antibodies against neurospecific enolase was less significant in the brain tissue of the contralateral hemisphere and cerebellum not exposed to ischemia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15665940     DOI: 10.1007/s10517-005-0037-4

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  2 in total

1.  Blocking TLR2 in vivo protects against accumulation of inflammatory cells and neuronal injury in experimental stroke.

Authors:  Gina Ziegler; Dorette Freyer; Denise Harhausen; Uldus Khojasteh; Wilfried Nietfeld; George Trendelenburg
Journal:  J Cereb Blood Flow Metab       Date:  2010-09-15       Impact factor: 6.200

2.  Evaluation of the Therapeutic Potential of Anti-TLR4-Antibody MTS510 in Experimental Stroke and Significance of Different Routes of Application.

Authors:  Lena Andresen; Konstantina Theodorou; Sarah Grünewald; Bozena Czech-Zechmeister; Birte Könnecke; Fred Lühder; George Trendelenburg
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.